PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit ...

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

Health Headlines: From New Drug Sales to Genetic Breakthroughs In recent health news, Bristol Myers and Pfizer plan to sell Eliquis at a discount, aiming to aid uninsured patients. Meanwhile, the UK's ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...